CATALYSIS Advises Point-of-Care Diagnostic Developer Åmic AB in Sale to Johnson & Johnson Nordic AB

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive strategic advisor to Åmic AB in its sale to Johnson & Johnson Nordic AB, a Johnson & Johnson company.  Financial terms were not disclosed.

Åmic AB (Uppsala, Sweden) is a privately held POC diagnostic company developing the next generation of POC diagnostic tests using its proprietary microfluidic technology. The technology uses a moulded plastic device called the 4castchip®, and a state-of-the-art optical detection system for precise and sensitive quantification of immunoassays. The Company intends to launch the Forecast POC Diagnostic System with high-performance test kits for the cardiac markers NT-proBNP and cTnI. The marker specific test cartridge contains the 4castchip® in a user friendly format for rapid analysis of whole-blood patient samples at the point of care. The Forecast Reader is a low-cost analyser designed for fail-safe operation in hospital and primary care settings with full connectivity to laboratory information systems. For more information, visit www.jnj.com

Johnson & Johnson Nordic AB is a subsidiary of Johnson & Johnson. Johnson & Johnson Nordic AB (Solentuna, Sweden) is a sales and marketing company in the Medical Devices & Diagnostics segment.  Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers high quality in vitro diagnostic products that give health care professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that’s safe, the right type, and the right unit. Ortho-Clinical Diagnostics also brings sophisticated information management, testing technologies, automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit www.orthoclinical.com

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.